Catherine Novack
Stock Analyst at JonesTrading
(4.56)
# 938
Out of 4,339 analysts
128
Total ratings
39.4%
Success rate
21.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Catherine Novack
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRRO Korro Bio | Upgraded: Buy | $23 | $11.61 | +98.11% | 3 | May 8, 2026 | |
| DTIL Precision BioSciences | Initiated Coverage: Buy | $30 | $7.23 | +314.94% | 2 | Apr 16, 2026 | |
| TSX: MDNA Medicenna Therapeutics Corp. | Rated: Hold | n/a | $0.45 | - | 4 | Apr 10, 2026 | |
| RLYB Rallybio | Rated: Hold | n/a | $15.88 | - | 10 | Apr 10, 2026 | |
| WVE Wave Life Sciences | Maintained: Buy | $20 → $35 | $6.38 | +448.59% | 13 | Mar 26, 2026 | |
| IBIO iBio, Inc. | Initiated Coverage: Buy | $7 | $1.84 | +280.43% | 1 | Mar 2, 2026 | |
| LRMR Larimar Therapeutics | Maintained: Buy | $7 → $13 | $3.45 | +276.81% | 9 | Feb 24, 2026 | |
| PVLA Palvella Therapeutics | Maintained: Buy | $143 → $209 | $113.99 | +83.35% | 7 | Feb 24, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintained: Buy | $85 → $97 | $36.79 | +163.66% | 15 | Jan 5, 2026 | |
| SEPN Septerna | Initiated Coverage: Buy | $43 | $28.36 | +51.62% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $33 | $4.54 | +626.87% | 1 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 | $28.87 | +0.45% | 8 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $9 | $1.55 | +480.65% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $17.37 | +72.71% | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $1.56 | n/a | 3 | May 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $3.25 | n/a | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $6 | $0.438 | n/a | 8 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $2.37 | n/a | 6 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $0.6289 | n/a | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.26 | n/a | 4 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 → $60 | $2.88 | n/a | 4 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $6.06 | n/a | 4 | Nov 15, 2021 |
Korro Bio
May 8, 2026
Upgraded: Buy
Price Target: $23
Current: $11.61
Upside: +98.11%
Precision BioSciences
Apr 16, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $7.23
Upside: +314.94%
Medicenna Therapeutics Corp.
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $0.45
Upside: -
Rallybio
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $15.88
Upside: -
Wave Life Sciences
Mar 26, 2026
Maintained: Buy
Price Target: $20 → $35
Current: $6.38
Upside: +448.59%
iBio, Inc.
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $1.84
Upside: +280.43%
Larimar Therapeutics
Feb 24, 2026
Maintained: Buy
Price Target: $7 → $13
Current: $3.45
Upside: +276.81%
Palvella Therapeutics
Feb 24, 2026
Maintained: Buy
Price Target: $143 → $209
Current: $113.99
Upside: +83.35%
Crinetics Pharmaceuticals
Jan 5, 2026
Maintained: Buy
Price Target: $85 → $97
Current: $36.79
Upside: +163.66%
Septerna
Dec 23, 2025
Initiated Coverage: Buy
Price Target: $43
Current: $28.36
Upside: +51.62%
Sep 30, 2025
Initiated Coverage: Buy
Price Target: $33
Current: $4.54
Upside: +626.87%
Sep 25, 2025
Maintained: Buy
Price Target: $29
Current: $28.87
Upside: +0.45%
Aug 8, 2025
Maintained: Buy
Price Target: $6 → $9
Current: $1.55
Upside: +480.65%
Jun 25, 2025
Initiated Coverage: Buy
Price Target: $30
Current: $17.37
Upside: +72.71%
May 17, 2025
Reiterated: Buy
Price Target: $11
Current: $1.56
Upside: n/a
May 15, 2025
Reiterated: Buy
Price Target: $12
Current: $3.25
Upside: n/a
May 13, 2025
Maintained: Buy
Price Target: $10 → $6
Current: $0.438
Upside: n/a
Nov 15, 2024
Reiterated: Buy
Price Target: $13
Current: $2.37
Upside: n/a
Nov 15, 2024
Reiterated: Buy
Price Target: $15
Current: $0.6289
Upside: n/a
Oct 31, 2024
Downgraded: Hold
Price Target: n/a
Current: $2.26
Upside: n/a
Jun 3, 2024
Maintained: Buy
Price Target: $160 → $60
Current: $2.88
Upside: n/a
Nov 15, 2021
Downgraded: Hold
Price Target: n/a
Current: $6.06
Upside: n/a